Dosing has begun in a new regimen of the HEALEY ALS platform trial, its ninth, which is testing the oral therapy NUZ-001 for ...

The MarketWatch News Department was not involved in the creation of this content. This funding was awarded through the ALS Association's Hoffman ALS Clinical Trial Awards Program, which aims to ...

MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage ...

First clinical development program in sporadic ALS patients to show potential to restore STATHMIN-2 expression, a statistically significant effect on a neurofilament biomarker, and an overall trend of ...

AB Science says a newly identified blood biomarker may help assess masitinib activity in its ongoing Phase 3 ALS clinical trial.

12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation Previous results showed PrimeC slowed disease progression by 36% and improved ...

Highlights: First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating ...

Neurizon hopes to initiate its regimen of the HEALEY-ALS trial in Q4 2025. Image credit: MAXIMUM ART / Shutterstock.com The US Food and Drug Administration (FDA) has released its clinical hold on ...

SAN FRANCISCO--(BUSINESS WIRE)--Unlearn ®, a pioneering artificial intelligence company, today announced a groundbreaking partnership with German-based APST Research (APST), a leading platform for ALS ...

The growing burden of ALS in the US highlights the need for earlier diagnosis, multidisciplinary care, and expanded access to emerging therapies.

This funding was awarded through the ALS Association's Hoffman ALS Clinical Trial Awards Program, which aims to accelerate the development of new ALS treatments ARLINGTON, Va., Dec. 4, 2025 ...